Overview

Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclosporine
Cyclosporins